These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 33796443)
21. Tuberculous Granuloma in the Scrotal Skin After Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer: A Case Report. Shimura H; Ihara T; Mitsui T; Takeda M Urol Case Rep; 2017 Feb; 11():4-6. PubMed ID: 28083473 [TBL] [Abstract][Full Text] [Related]
22. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer. Miyazaki J; Onozawa M; Takaoka E; Yano I Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322 [TBL] [Abstract][Full Text] [Related]
23. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868 [TBL] [Abstract][Full Text] [Related]
24. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer. Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038 [TBL] [Abstract][Full Text] [Related]
25. Jain H; Gada K; Zaidi S; Asiago-Reddy E; Eranki A Proc (Bayl Univ Med Cent); 2019 Oct; 32(4):577-578. PubMed ID: 31656426 [TBL] [Abstract][Full Text] [Related]
31. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426 [TBL] [Abstract][Full Text] [Related]
32. Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study. Nishiyama N; Kitamura H; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Masumori N Jpn J Clin Oncol; 2014 Nov; 44(11):1101-8. PubMed ID: 25139163 [TBL] [Abstract][Full Text] [Related]
33. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer. Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496 [TBL] [Abstract][Full Text] [Related]
34. Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy. Zheng YQ; Naguib YW; Dong Y; Shi YC; Bou S; Cui Z Expert Rev Vaccines; 2015; 14(9):1255-75. PubMed ID: 26268434 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. Boehm BE; Cornell JE; Wang H; Mukherjee N; Oppenheimer JS; Svatek RS J Urol; 2017 Sep; 198(3):503-510. PubMed ID: 28286068 [TBL] [Abstract][Full Text] [Related]
38. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer. Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686 [TBL] [Abstract][Full Text] [Related]
39. Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report. Sampaio PCM; Lira YG; Ribeiro HYU; de Paula Moreira F; Gadelha MSM; da Cruz SFS BMC Res Notes; 2017 Aug; 10(1):416. PubMed ID: 28821265 [TBL] [Abstract][Full Text] [Related]
40. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer. Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]